One in Two

In this episode, we speak to Dr Colin Lindsay, Clinical Senior Lecturer at The Christie and The University of Manchester about the basic biology of lung cancer, focusing on:   The high incidence of lung cancer here in Manchester The differences between non-small cell and small-cell lung cancer Oncogenic drivers in lung cancer such as the KRAS mutation His work on the drug sotorasib which targets KRAS mutant cancer and has now been approved by the FDA and for use in the UK by NICE     Colin Lindsay's research profile   EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells   KRAS: Reasons for optimism in lung cancer  On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma  Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial Molecular characterization of primary and secondary resistance to RET inhibitors in patients with advanced NSCLC and RET fusions (2022) https://www.ejcancer.com/article/S0959-8049(22)00871-1/fulltext  

Show Notes

 In this episode, we speak to Dr Colin Lindsay, Clinical Senior Lecturer at The Christie and The University of Manchester about the basic biology of lung cancer, focusing on:
  
  •  The high incidence of lung cancer here in Manchester
  •  The differences between non-small cell and small-cell lung cancer
  •  Oncogenic drivers in lung cancer such as the KRAS mutation
  •  His work on the drug sotorasib which targets KRAS mutant cancer and has now been approved by the FDA and for use in the UK by NICE
  
  
 Colin Lindsay's research profile
  
EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells
  
KRAS: Reasons for optimism in lung cancer 
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma 
 Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
 Molecular characterization of primary and secondary resistance to RET inhibitors in patients
with advanced NSCLC and RET fusions (2022) https://www.ejcancer.com/article/S0959-8049(22)00871-1/fulltext
 

What is One in Two?

With one in two of us receiving a cancer diagnosis at some point during our lives, it has never been more important to improve the outcomes for people affected by cancer.

This cancer research podcast is brought to you by The University of Manchester in partnership with the Manchester Cancer Research Centre (MCRC). In each episode, our cancer researchers discuss the innovations, discoveries and projects that are changing the landscape of early detection.